Advertisement
Advances in Pediatrics

The Antiphospholipid Syndrome in the Pediatric Population

  • Elizabeth E. Sloan
    Correspondence
    Corresponding author.
    Affiliations
    Department of Pediatrics, Division of Rheumatology, University of Texas Southwestern Medical Center, Scottish Rite for Children and Children's Medical Center Dallas, 2222 Welborn Street, Dallas, TX 75219, USA
    Search for articles by this author
  • Deborah McCurdy
    Affiliations
    Department of Pediatrics, Division of Allergy/Immunology/Rheumatology, David Geffen School of Medicine, UCLA, Mattel Children’s Hospital, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Pediatrics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Miyakis S.
        • Lockshin M.D.
        • Atsumi T.
        • et al.
        International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
        J Thromb Haemost. 2006; 4: 295-306
        • Garcia D.
        • Erkan D.
        Diagnosis and Management of the Antiphospholipid Syndrome.
        N Engl J Med. 2018; 378: 2010-2021
        • McIntyre J.A.
        • Wagenknecht D.R.
        • Faulk W.P.
        Antiphospholipid antibodies: discovery, definitions, detection and disease.
        Prog Lipid Res. 2003; 42: 176-237
        • Pierangeli S.S.
        • Chen P.P.
        • Raschi E.
        • et al.
        Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.
        Semin Thromb Hemost. 2008; 34: 236-250
        • Cervera R.
        • Piette J.C.
        • Font J.
        • et al.
        Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.
        Arthritis Rheum. 2002; 46: 1019-1027
        • Avcin T.
        • Cimaz R.
        • Rozman B.
        The Ped-APS registry: the antiphospholipid syndrome in childhood.
        Lupus. 2009; 18: 894-899
        • Avcin T.
        • Cimaz R.
        • Silverman E.D.
        • et al.
        Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry.
        Pediatrics. 2008; 122: e1100-e1107
        • Moulton V.R.
        • Suarez-Fueyo A.
        • Meidan E.
        • et al.
        Pathogenesis of human systemic lupus erythematosus: a cellular perspective.
        Trends Mol Med. 2017; 23: 615-635
        • Chaturvedi S.
        • McCrae K.R.
        Diagnosis and management of the antiphospholipid syndrome.
        Blood Rev. 2017; 31: 406-417
        • Arachchillage D.R.J.
        • Laffan M.
        Pathogenesis and management of antiphospholipid syndrome.
        Br J Haematol. 2017; 178: 181-195
        • Giannakopoulos B.
        • Krilis S.A.
        The pathogenesis of the antiphospholipid syndrome.
        N Engl J Med. 2013; 368: 1033-1044
        • Meng H.
        • Yalavarthi S.
        • Kanthi Y.
        • et al.
        In Vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis.
        Arthritis Rheumatol. 2017; 69: 655-667
        • Favaloro E.J.
        • Henry B.M.
        • Lippi G.
        COVID-19 and antiphospholipid antibodies: time for a reality check?.
        Semin Thromb Hemost. 2021; 48: 72-92
        • Zuo Y.
        • Estes S.K.
        • Ali R.A.
        • et al.
        Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19.
        Sci Transl Med. 2020; 12: eabd3876
        • Borghi M.O.
        • Beltagy A.
        • Garrafa E.
        • et al.
        Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome.
        Front Immunol. 2020; 11: 584241
        • Driest K.D.
        • Sturm M.S.
        • O'Brien S.H.
        • et al.
        Factors associated with thrombosis in pediatric patients with systemic lupus erythematosus.
        Lupus. 2016; 25: 749-753
        • Descloux E.
        • Durieu I.
        • Cochat P.
        • et al.
        Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies.
        Rheumatology (Oxford). 2008; 47: 183-187
        • Sciascia S.
        • Amigo M.C.
        • Roccatello D.
        • et al.
        Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.
        Nat Rev Rheumatol. 2017; 13: 548-560
        • Wincup C.
        • Ioannou Y.
        The differences between childhood and adult onset antiphospholipid syndrome.
        Front Pediatr. 2018; 6: 362
        • Berman H.
        • Rodríguez-Pintó I.
        • Cervera R.
        • et al.
        Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the "CAPS Registry".
        Autoimmun Rev. 2014; 13: 157-162
        • Meroni P.L.
        • Argolini L.M.
        • Pontikaki I.
        What is known about pediatric antiphospholipid syndrome?.
        Expert Rev Hematol. 2016; 9: 977-985
        • Francès C.
        • Papo T.
        • Wechsler B.
        • et al.
        Sneddon syndrome with or without antiphospholipid antibodies. a comparative study in 46 patients.
        Medicine (Baltimore). 1999; 78: 209-219
        • Di Prima F.A.
        • Valenti O.
        • Hyseni E.
        • et al.
        Antiphospholipid syndrome during pregnancy: the state of the art.
        J Prenat Med. 2011; 5: 41-53
        • De Carolis S.
        • Tabacco S.
        • Rizzo F.
        • et al.
        Antiphospholipid syndrome: An update on risk factors for pregnancy outcome.
        Autoimmun Rev. 2018; 17: 956-966
        • de Jesus G.R.
        • Agmon-Levin N.
        • Andrade C.A.
        • et al.
        14th international congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome.
        Autoimmun Rev. 2014; 13: 795-813
        • Rosina S.
        • Chighizola C.B.
        • Ravelli A.
        • et al.
        Pediatric antiphospholipid syndrome: from pathogenesis to clinical management.
        Curr Rheumatol Rep. 2021; 23: 10
        • Go E.J.L.
        • O'Neil K.M.
        The catastrophic antiphospholipid syndrome in children.
        Curr Opin Rheumatol. 2017; 29: 516-522
        • Pilania R.K.
        • Suri D.
        • Jindal A.K.
        • et al.
        Lupus anticoagulant hypoprothrombinemia syndrome associated with systemic lupus erythematosus in children: report of two cases and systematic review of the literature.
        Rheumatol Int. 2018; 38: 1933-1940
        • Ricarte I.F.
        • Dutra L.A.
        • Abrantes F.F.
        • et al.
        Neurologic manifestations of antiphospholipid syndrome.
        Lupus. 2018; 27: 1404-1414
        • Hughes G.R.
        Hughes' syndrome: the antiphospholipid syndrome. a historical view.
        Lupus. 1998; 7: S1-S4
        • Devreese K.M.J.
        • Zuily S.
        • Meroni P.L.
        Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome.
        J Transl Autoimmun. 2021; 4: 100134
        • Devreese K.M.J.
        • de Groot P.G.
        • de Laat B.
        • et al.
        Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the international society on thrombosis and haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation.
        J Thromb Haemost. 2020; 18: 2828-2839
        • Madison J.A.
        • Zuo Y.
        • Knight J.S.
        Pediatric antiphospholipid syndrome.
        Eur J Rheumatol. 2019; 7: 1-10
        • Tektonidou M.G.
        • Andreoli L.
        • Limper M.
        • et al.
        EULAR recommendations for the management of antiphospholipid syndrome in adults.
        Ann Rheum Dis. 2019; 78: 1296-1304
        • Groot N.
        • de Graeff N.
        • Avcin T.
        • et al.
        European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative.
        Ann Rheum Dis. 2017; 76: 1637-1641
        • Madison J.A.
        • Duarte-García A.
        • Zuo Y.
        • et al.
        Treatment of thrombotic antiphospholipid syndrome in adults and children.
        Curr Opin Rheumatol. 2020; 32: 215-227
        • Pengo V.
        • Denas G.
        • Zoppellaro G.
        • et al.
        Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
        Blood. 2018; 132: 1365-1371
        • Ordi-Ros J.
        • Sáez-Comet L.
        • Pérez-Conesa M.
        • et al.
        Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial.
        Ann Intern Med. 2019; 171: 685-694
        • Malec K.
        • Góralczyk T.
        • Undas A.
        The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
        Thromb Res. 2017; 152: 93-97
        • Dufrost V.
        • Risse J.
        • Zuily S.
        • et al.
        Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? a systematic review of the literature.
        Curr Rheumatol Rep. 2016; 18: 74
        • Bala M.M.
        • Paszek E.
        • Lesniak W.
        • et al.
        Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies.
        Cochrane Database Syst Rev. 2018; 7: Cd012534
        • Erkan D.
        • Harrison M.J.
        • Levy R.
        • et al.
        Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals.
        Arthritis Rheum. 2007; 56: 2382-2391
        • Zuo Y.
        • Barbhaiya M.
        • Erkan D.
        Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?.
        Curr Rheumatol Rep. 2018; 20: 66
        • Arnaud L.
        • Mathian A.
        • Devilliers H.
        • et al.
        Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies.
        Autoimmun Rev. 2015; 14: 192-200
        • Sloan E.
        • Wright T.
        • Zuo Y.
        Identifying additional risk factors for arterial and venous thrombosis among pediatric antiphospholipid antibodies carriers.
        Lupus. 2021; 30: 828-832
        • Sammaritano L.R.
        Which hormones and contraception for women with APS? exogenous hormone use in women with APS.
        Curr Rheumatol Rep. 2021; 23: 44
        • Mantha S.
        • Karp R.
        • Raghavan V.
        • et al.
        Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis.
        BMJ. 2012; 345: e4944
        • Duarte-García A.
        • Pham M.M.
        • Crowson C.S.
        • et al.
        The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study.
        Arthritis Rheumatol. 2019; 71: 1545-1552